A first-of-its kind genetic treatment for blindness will cost $US850,000 ($A1.2 million), less than the $US1 million price tag that had been expected, but it's still among the most expensive genetic therapies in the world.
Spark Therapeutics says it decided on the lower price tag for Luxturna, after hearing from health insurers about their ability to cover the injectable treatment.
Consternation over skyrocketing drug prices, especially in the US, has led to intense scrutiny from patients, Congress, insurers and hospitals.
Luxturna, approved last month, is the nation's first gene therapy for an inherited disease. It can improve the vision of those with a rare form of blindness that affects just a few thousand people in the US.
Share
